Efficacy and safety of COVID-19 vaccines in children aged 5 to 11 years

Authors

  • Francisco José Riveros Montero Estudiante de Medicina, Facultad de Medicina, Universidad Católica del Norte https://orcid.org/0000-0002-5309-2274
  • Francisco Javier Díaz Moreno Estudiante de Medicina, Facultad de Medicina, Universidad Católica del Norte https://orcid.org/0009-0006-8327-2977
  • Brandon Andrés Rodríguez Cortés Estudiante de Medicina, Facultad de Medicina, Universidad Católica del Norte https://orcid.org/0009-0006-8113-5709
  • Emilia Antonia Acuña Arcos Estudiante de Medicina, Facultad de Medicina, Universidad Católica del Norte https://orcid.org/0009-0006-0305-7469
  • Issadora Antonia Meriño Donoso Estudiante de Medicina, Facultad de Medicina, Universidad Católica del Norte https://orcid.org/0009-0004-3334-101X
  • Sergio Eduardo Riveros Moreno Médico de Familia, La Serena https://orcid.org/0009-0001-9641-9118
  • Patricio Enrique Vargas Reyes Médico Pediatra, Académico Departamento de Clínica, Universidad Católica del Norte

DOI:

https://doi.org/10.52611/confluencia.2026.1916

Keywords:

COVID-19 vaccine, Children, Adolescents, Safety, Efficacy

Abstract

Introduction: COVID-19 is typically mild in children, but severe cases, such as multisystem inflammatory syndrome, can occur. Vaccination is the primary preventive strategy. Methodology: A literature review was conducted using a structured search (2020–2025) with MeSH/DeCS terms. Systematic reviews, meta-analyses, randomized controlled trials, and large-scale cohort studies that evaluated the safety and efficacy of vaccinations were selected. Result: mRNA vaccines show an initial efficacy of 90% against symptomatic disease and 96% against severe disease, with efficacy decreasing against the Omicron variant but maintaining high protection against hospitalizations. Adverse effects are mild and self-limiting (6-10%); the risk of myocarditis is low in children under 12 years of age, at 1,8 cases per million. In Chile, the inactivated CoronaVac vaccine demonstrated 64,6% effectiveness against the Omicron variant in preventing hospitalizations and 69% effectiveness in preventing Intensive Care Units admissions. Discussion: The risk-benefit balance favors childhood immunization compared to the risks of natural infection and its sequelae. Conclusions: Pediatric vaccination against COVID-19 is a safe and effective intervention. Immunization policies should be adapted to local epidemiology while ensuring equity.

References

1. Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. Lancet Child Adolesc Health [Internet]. 2023 [citado el 1 de agosto 2026];7(6):379-91. Disponible en: http://dx.doi.org/10.1016/S2352-4642(23)00078-0

2. Wen J, Du X, Li A, Zhang S, Shen S, Zhang Z, et al. Dilemmas and options for COVID-19 vaccination in children. Ital J Pediatr [Internet]. 2023 [citado el 1 de agosto 2026];49(1):103. Disponible en: http://dx.doi.org/10.1186/s13052-023-01513-9

3. da Fonseca Lima EJ, Leite RD. COVID-19 vaccination in children: a public health priority. J Pediatr (Rio J) [Internet]. 2023 [citado el 1 de agosto 2026];99:S28-S36. Disponible en: http://dx.doi.org/10.1016/j.jped.2022.11.006

4. Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci [Internet]. 2022 [citado el 1 de agosto 2026];29(1):82. Disponible en: http://dx.doi.org/10.1186/s12929-022-00853-8

5. Jara A, Undurraga EA, Zubizarreta JR, González C, Acevedo J, Pizarro A, et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med [Internet]. 2022 [citado el 1 de agosto 2026];28(7):1377-80. Disponible en: http://dx.doi.org/10.1038/s41591-022-01874-4

6. Howard-Jones AR, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, et al. COVID‐19 in children: I. Epidemiology, prevention and indirect impacts. J Paediatr Child Health [Internet]. 2022 [citado el 1 de agosto 2026];58(1):39-45. Disponible en: http://dx.doi.org/10.1111/jpc.15791

7. Jantarabenjakul W, Chantasrisawad N, Nantanee R, Ganguli S, Puthanakit T. Global COVID-19 Vaccination in Infants and Children: Effectiveness, Safety, and Challenges. Asian Pac J Allergy Immunol [Internet]. 2023 [citado el 1 de agosto 2026];41(4):292-303. Disponible en: https://doi.org/10.12932/ap-300423-1596

8. Howard-Jones AR, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, et al. COVID‐19 in children. II: Pathogenesis, disease spectrum and management. J Paediatr Child Health [Internet]. 2022 [citado el 1 de agosto 2026];58(1):46-53. Disponible en: http://dx.doi.org/10.1111/jpc.15811

9. Sun YK, Wang C, Lin PQ, Hu L, Ye J, Gao ZG, et al. Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives. World J Pediatr [Internet]. 2024 [citado el 1 de agosto 2026];20(4):307-24. Disponible en: http://dx.doi.org/10.1007/s12519-023-00790-y

10. Azeem M, Cancemi P, Mukhtar F, Marino S, Peri E, Di Prima G, et al. Efficacy and limitations of SARS-CoV-2 vaccines - A systematic review. Life Sci [Internet]. 2025 [citado el 1 de agosto 2026];371:123610. Disponible en: http://dx.doi.org/10.1016/j.lfs.2025.123610

11. Munro APS, Jones CE, Faust SN. Vaccination against COVID-19 - risks and benefits in children. Eur J Pediatr [Internet]. 2024 [citado el 1 de agosto 2026];183(3):1107-12. Disponible en: http://dx.doi.org/10.1007/s00431-023-05380-8

12. Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines (Basel) [Internet]. 2021 [citado el 1 de agosto 2026];9(10):1102. Disponible en: http://dx.doi.org/10.3390/vaccines9101102

13. Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials. J Med Virol [Internet]. 2022 [citado el 1 de agosto 2026];94(10):4644-53. Disponible en: http://dx.doi.org/10.1002/jmv.27940

14. Hu YH, Ding Y, Li LW, Cheng J, Cai YH. Evaluation of vaccine effectiveness of mRNA COVID-19 vaccines in children: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci [Internet]. 2024 [citado el 1 de agosto 2026];28(6):2584-92. Disponible en: http://dx.doi.org/10.26355/eurrev_202403_35764

15. Fayad D, Frenck RW Jr. COVID-19 Vaccines in Children. J Clin Med [Internet]. 2023 [citado el 1 de agosto 2026];13(1):87. Disponible en: https://doi.org/10.3390/jcm13010087

16. Hart JD, Ong DS, Chokephaibulkit K, Ong-Lim AT, Vereti I, Crawford NW, et al. Considerations for vaccinating children against COVID-19. BMJ Paediatr Open [Internet]. 2023 [citado el 1 de agosto 2026];7(1):e001964. Disponible en: http://dx.doi.org/10.1136/bmjpo-2023-001964

17. Jara A, Undurraga EA, Flores JC, Zubizarreta JR, González C, Pizarro A, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. Lancet Reg Health Am [Internet]. 2023 [citado el 1 de agosto 2026];21:100487. Disponible en: http://dx.doi.org/10.1016/j.lana.2023.100487

Downloads

Published

2026-11-17

Issue

Section

Literature Review

How to Cite

1.
Riveros Montero FJ, Díaz Moreno FJ, Rodríguez Cortés BA, Acuña Arcos EA, Meriño Donoso IA, Riveros Moreno SE, et al. Efficacy and safety of COVID-19 vaccines in children aged 5 to 11 years. Rev Conflu [Internet]. 2026 Nov. 17 [cited 2026 Nov. 20];9. Available from: https://revistas.udd.cl/index.php/confluencia/article/view/1916

Downloads

Download data is not yet available.

Societal impact

Most read articles by the same author(s)